CFN Media

December 14, 2016 09:41 ET

InMed Pharma (IMLFF): Canadian Cannabis Biopharma Backed by Seasoned Management -- CFN Media

SEATTLE, WA--(Marketwired - Dec 14, 2016) -  CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, today announced the publication of an article and video CEO interview discussing InMed Pharmaceuticals Ltd.'s (OTCQB: IMLFF) (CSE: IN) uniquely efficient approach to the burgeoning cannabis biopharmaceutical industry.

The pharmaceutical industry represents the single largest subset of the cannabis industry, according to Bloomberg's 2015 Weed Index; this market had a combined market capitalization of over $1.5 billion. Since then, GW Pharmaceuticals plc's market capitalization alone has soared to nearly $3 billion and increased the value of the pharmaceutical side of the business well beyond producers, dispensaries, real estate, consulting, and other industry subsets.

The most important indicator of success for many micro-cap companies is their management team since there's often no existing revenue or profit. InMed Pharmaceuticals' management team has combined experience in drug development, regulatory affairs, business development, sales and marketing, and capital formation.

Dr. Ado Muhammad, MD, DPM, MFPM, became the company's Chief Medical Officer after serving as the Associate Medical Director for GW Pharmaceuticals plc, specializing in the development of cannabinoid-based prescription medicines. He is the only former Senior GW team member, that we are aware of, currently involved with a cannabinoid biopharmaceutical company in all of North America. A recent new hire, Sr. VP of Clinical and Regulatory Affairs, Alexandra Mancini, M.Sc., was instrumental in securing approval for the anticancer drug PHOTOFRIN® and its associated medical devices when working with QLT Inc., along with several other drugs in the ocular, dermatological and diagnostics segments. 

Low-Risk Approach

The average cost of taking a pharmaceutical drug from pre-clinical trials to an FDA approval is approximately $1.4 billion, according to The Tufts Center for the Study of Drug Development. While many development-stage pharmaceutical companies are acquired if successful after Phase II clinical trials, shareholders still face significant dilution over time to bring drugs from pre-clinical stages to complete Phase II clinical trials.

InMed Pharmaceuticals has developed an approach that reduces the cost, time and associated risks to bringing cannabinoids to market. Using a proprietary bioinformatics analysis tool, the company can rapidly identify specific cannabinoids (of the 90+ in the cannabis plant) that could play a role in treating specific diseases by looking at the structures of approved and researched drugs, genetic profiles of diseases, and other factors. This helps reduce the time to market and increase the likelihood of success. InMed has developed its two lead compounds through this system, INM-750 for Epidermolysis Bullosa and INM-085 for Glaucoma. Also, using natural compounds with well-understood safety profiles contributes significantly to reduced risk of clinical failure due to safety issues.

Follow the link to read the full article and see the interview with CEO Eric A. Adams:

Learn how to become a CFN Media client company, brand or entrepreneur:

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand:

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone:

About CFN Media

CFN Media (CannabisFN), the leading creative agency and media network dedicated to legal cannabis, helps marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.


Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit:

Contact Information